Loading clinical trials...

Immunogenicity Induced by COVID-19 Vaccines in Mexican Population | Clinical Trials | Clareo Health

COMPLETED

Immunogenicity Induced by COVID-19 Vaccines in Mexican Population

Immunogenicity Induced by COVID-19 Vaccines in Mexican Population: mRNA Expression for IgG Anti-spike

NCT06597370•National Polytechnic Institute, Mexico

Summary

To determine the gene expression of anti-spike IgG through PCR-RT in patients vaccinated with the 4 types of vaccines available in Mexico Oxford/AstraZeneca (ChAdOx1 nCoV-19), Centro Nacional Gamaleya (Sputnik V), Pfizer/BioNTech (BNT162b2) and Sinovac (CoronaVac).

Detailed Description

80 subjects with full vaccination schedule will be included, 20 per group To know the gene expression of IgG anti-spike through PCR-RT in patients vaccinated with the 4 types of vaccines available in Mexico Oxford/AstraZeneca (ChAdOx1 nCoV-19), Centro Nacional Gamaleya (Sputnik V), Pfizer/BioNTech (BNT162b2) and Sinovac (CoronaVac).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. \- Mexican people.
•2. \- Over 18 years of age.
•3. \- With complete vaccination schedule against COVID-19.
•4. \- Allowing peripheral blood samples to be taken.
•5. \- To sign an informed consent form.
•6. \- To agree to participate in the protocol.

Exclusion Criteria

•1. \- Persons with incomplete vaccination schedule against COVID-19.
•2. \- Persons who have 30 +/- 5 days of having completed the vaccination scheme against COVID-19.
•3. \- People under treatment with any immunosuppressive drug.
•4. People who refuse to sign the informed consent form.

Locations (1)

Escuela Superior de Medicina, Instituto Politécnico Nacional

Mexico City, Mexico

Key Dates

Start Date

September 1, 2021

Primary Completion Date

December 20, 2021

Completion Date

December 21, 2021

Last Updated

October 4, 2024

Enrollment

ACTUAL participants

Conditions

COVID-19 Vaccine

Interventions

Gene expression mRNA of IgG anti-spike

OTHER

Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health

NCT05553743

BreastfeedingCOVID-19 Infection+3 more

View study

ACTIVE_NOT_RECRUITINGPHASE3

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

NCT05556720

HIVOrgan Transplantation+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 4, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Immunogenicity Induced by COVID-19 Vaccines in Mexican Population

Inclusion Criteria

Exclusion Criteria

Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)

Safety Study About the mRNA Vaccines Against COVID-19 in Children (PEDIVACOV-HCSC)

INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old